NAS8
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
06/16/2026
Back to search
Official data from USPTO
4C PHARMA SOLUTIONS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
4C PHARMA SOLUTIONS
ST13
US500000088232337Class
35, 41, 42, 44, 45
Filing
88232337
Registration
5849323
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
34
Latest update
06/17/2026
Trademark type
Word
Nice classes
35, 41, 42, 44, 45
Filing date
12/17/2018
Registration date
09/03/2019
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/16/2026
Last transaction
06/17/2026
Responsible office
United States Patent and Trademark Office
Status code
701
Official register
Principal Register
First use anywhere
09/08/2018
First use in commerce
09/08/2018
Drawing code
4
Owner type
16
Owner location
Piscataway, NJ, US
Examiner
WILKE, JOHN
Current location
Historical data usage
Holders and representatives
Holders
4C Pharma Solutions LLC
Representatives
ESTEBAN O'FARRELL
Technical classification
Nice Classes
Class 35Class 41Class 42Class 44Class 45
Vienna Codes
No Vienna codes available.
Goods and services
Class 35
Regulatory submission managementassisting others in preparing and filing applications for new drugsgeneric drugsmedical devicesdrug/device combinationsbiologicsbiosimilarsnutraceuticalsconsumer products or cosmetics with governmental regulatory bodies; business consulting and management in the field of clinical trialsclinical data and regulatory submission management on behalf of medicalbiopharmaceutical and biotechnology companies to assist them with clinical researchclinical trials and applications for new druggeneric drugmedical devicedrug/device combinationbiologicbiosimilarnutraceuticalconsumer product or cosmetic approval; regulatory submission managementassisting others in preparing and filing applications for new drugsgeneric drugsmedical devicesdrug/device combinationsbiologicsbiosimilarsnutraceuticalsconsumer products or cosmetics with governmental regulatory bodies; providing consulting services in the field of regulatory submission management to companies to assist them with applications for new druggeneric drugmedical devicedrug/device combinationbiologicbiosimilarnutraceuticalconsumer product or cosmetic approval; interactive record-keeping services for use in risk management and regulatory compliance by insurers and professionals in the medical field; business risk assessment services
Class 41
Training services in the field of pharmacovigilance and regulatory compliance
Class 42
Technical writing for others; technical writing in the field of medical writing; searching and retrieving informationsitesother resources available on computer networks for others; consulting services for others in the field of designplanningimplementation project management of clinical trials and pharmacovigilance; installation and maintenance of pharmacovigilance computer software; tracking and monitoring of safety and/or efficacy for drugsdevicesdrug/device combinationsbiologicsbiosimilarscosmeticsnutraceuticals or consumer products for others for pharmacovigilance purposes
Class 44
Providing medical information in the field of pharmacovigilance and clinical trials
Class 45
Regulatory compliance consulting in the field of prescription drug sampling; tracking and monitoring regulatory requirements in the field of new drugsgeneric drugsmedical devicesdrug/device combinationsbiologicsbiosimilarsnutraceuticalsconsumer products or cosmetics for regulatory compliance purposes; regulatory compliance consulting in the field of new drugsgeneric drugsmedical devicesdrug/device combinationsbiologicsbiosimilarsnutraceuticalsconsumer products or cosmetics
Publications
History of USPTO decisions and trademark events.
34 publications found
8.OK
REGISTERED - SEC. 8 (6-YR) ACCEPTED
06/16/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
06/15/2026
ES8R
TEAS SECTION 8 RECEIVED
03/02/2026
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
02/27/2026
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
02/27/2026
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
02/27/2026
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
02/27/2026
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
02/27/2026
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
09/03/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
09/03/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/18/2019
PUBO
PUBLISHED FOR OPPOSITION
06/18/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/29/2019
FIXD
ELECTRONIC RECORD REVIEW COMPLETE
05/15/2019
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
05/10/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/03/2019
XAEC
EXAMINER'S AMENDMENT ENTERED
05/03/2019
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
05/03/2019
GNEA
EXAMINERS AMENDMENT E-MAILED
05/03/2019
CNEA
EXAMINERS AMENDMENT -WRITTEN
05/03/2019
ZZAX
PREVIOUS ALLOWANCE WITHDRAWN-TIMELY AAU
05/03/2019
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
05/02/2019
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
04/23/2019
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
04/11/2019
ALIE
ASSIGNED TO LIE
04/10/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/18/2019
XAEC
EXAMINER'S AMENDMENT ENTERED
03/18/2019
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
03/18/2019
GNEA
EXAMINERS AMENDMENT E-MAILED
03/18/2019
CNEA
EXAMINERS AMENDMENT -WRITTEN
03/18/2019
DOCK
ASSIGNED TO EXAMINER
03/13/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/08/2019
NWAP
NEW APPLICATION ENTERED
12/20/2018
Continuous trademark protection
Get notified about every new filing that threatens 4C PHARMA SOLUTIONS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.